ZEOX · Zeo ScientifiX, Inc. · Exempt Offerings
Substantial doubt about the company's ability to continue as a going concern.
“As of April 30, 2026, based on the factors described above, the Company concluded that there was substantial doubt about its ability to continue to operate as a going concern for the 12 months following the issuance of these financial statements. In addition, the Company's independent registered public accounting firm, in its report on the Company's October 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Jun 15, 2026
One customer — 14.2% of revenue (the six months ended April 30, 2026)
“During the six months ended April 30, 2026, the Company sold products and services totaling approximately $571,000 (14.2%) to a large medical practice group and distributor”
One customer — 12.7% of revenue (the six months ended April 30, 2026)
“and approximately $511,000 (12.7%) to another large medical practice group and distributor.”
One customer — 15.2% of revenue (the six months ended April 30, 2025)
“$341,000 (15.2%)”
One customer — 12.1% of revenue (the six months ended April 30, 2025)
“During the six months ended April 30, 2025, the Company sold products and services totaling approximately $270,000 (12.1%) to a large distributor”
One customer — 10.2% of revenue (the six months ended April 30, 2025)
“and $228,000 (10.2%) to two individual medical practices.”
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.